

DAU 1642 Lp  
10-2-98  
R2

ALLIA.143CP2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : H. Zaghouani ) Group Art Unit Unknown  
Serial No. : 09/111,123 )  
Filed : July 6, 1998 )  
For : COMPOUNDS, COMPOSITIONS )  
AND METHODS FOR THE )  
ENDOCYTIC PRESENTATION OF )  
IMMUNOSUPPRESSIVE )  
FACTORS )  
Examiner : Unknown )

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

September 23, 1998

Christopher A. Dayton, Reg. No. 35,114

TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) Enclosed is form PTO-1449 listing references that were either cited or submitted in a prior application, PCT Application No. US98/00520, filed January 7, 1998, which is a continuation-in-part of 08/779,767, filed January 7, 1997, on which the present application relies for an earlier filing date under 35 U.S.C. § 120. Therefore, in accordance with 37 C.F.R. § 1.98 (d), copies are not submitted.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment, to Account No. 01-1008. A duplicate copy of this sheet is enclosed.
- (X) Return prepaid postcard.

RECEIVED

98 OCT -1 PM 1:57

GROUP 180

Christopher A. Dayton  
Registration No. 35,114  
Attorney of Record

ALLIA.143CP2




PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	H. Zaghouani	)	Group Art Unit Unknown
			)	
Serial No.	:	09/111,123	)	
			)	
Filed	:	July 6, 1998	)	
			)	
For	:	COMPOUNDS, COMPOSITIONS AND METHODS FOR THE ENDOCYTIC PRESENTATION OF IMMUNOSUPPRESSIVE FACTORS	)	I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on
			)	
Examiner	:	Unknown	)	
			)	

September 23, 1998,

  
Christopher A. Dayton, Reg. No. 35,114

98 OCT - 1 PM 1:57  
GROUP 180  


INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing references that were either cited or submitted in a prior application, PCT Application No. US98/00520, filed January 7, 1998, which is a continuation-in-part of 08/779,767, filed January 7, 1997, on which the present application relies for an earlier filing date under 35 U.S.C. § 120. Therefore, in accordance with 37 C.F.R. § 1.98 (d), copies are not submitted.

This Information Disclosure Statement is being filed within three months of the filing date of this application, and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1). However, if a fee is required, the Commissioner is hereby authorized to charge any additional fees, which may be required, to Account No. 01-1008. A duplicate copy of this sheet is enclosed.

**Serial No.** : 09/111,123  
**Filed** : July 6, 1998

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made; and shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b). Further, Applicant makes no representation regarding the completeness of this list or that better art does not exist.

Respectfully submitted,

Dated: 9/23/98

By:   
Christopher A. Dayton  
Registration No. 35,114  
Attorney of Record


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. ALLIA.143CP2	APPLICATION NO. 09/111,123
<b>INFORMATION DISCLOSURE STATEMENT</b> <b>APPLICANT</b> <small>(USE SEVERAL SHEETS IF NECESSARY)</small>		APPLICANT H. Zaghouani	
		FILING DATE July 6, 1998	GROUP Unknown

									FOREIGN PATENT DOCUMENTS				
EXAMINER INITIAL	D N	O U	C M	U B	M E	E R	N	T	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	9	6	1	6	0	8	6		05/30/96	PCT			
	9	4	1	4	8	4	7		07/07/94	PCT			
	9	6	3	4	6	2	2		11/07/96	PCT			
	9	5	2	3	8	1	4		09/08/95	PCT			
	9	3	1	0	2	2	0		05/27/93	PCT			
	9	4	2	8	0	2	7		12/8/94	PCT			

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	A.	Ashton-Rickardt, et al. "Evidence for a Differential Avidity Model of T Cell Selection in the Thymus" <i>Cell</i> <b>76</b> : 651-663 (1994).
	B.	Brocke, et al. "Treatment of Experimental Encephalomyelitis with a Peptide Analogue of Myelin Basic Protein" <i>Nature</i> <b>379</b> : 343-346 (25 January 1996).
	C.	Chou, et al. "Frequency of T Cells Specific for Myelin Basic Protein and Myelin Proteolipid Protein in Blood and Cerebrospinal Fluid in Multiple Sclerosis" <i>J. of Neuroimmunology</i> <b>38</b> : 105-114 (1992).
	D.	Cibotti, et al. "Tolerance to a Self-Protein Involves Its Immunodominant But Does Not Involve Its Subdominant Determinants" <i>Proc. Natl. Acad. Sci. USA</i> <b>89</b> : 416-420 (1992).
	E.	De Magistic, et al. "Antigen Analog-Major Histocompatibility Complexes Act as Antagonists of the T Cell Receptor" <i>Cell</i> <b>68</b> : 625-634 (1992).

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE	 ATTY DOCKET NO. ALLIA.143CP2	APPLICATION NO. 09/111,123
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(USE SEVERAL SHEETS IF NECESSARY)</small>		<b>APPLICANT</b> H. Zaghouani
	<b>FILING DATE</b> July 6, 1998	<b>GROUP</b> Unknown

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	F.	Min, et al. "Modulation in Vivo of Autoreactive T Cells by a TCR Antagonist Ig Chimera" J. of Allergy Clinical Immunology 99(1):738 (January 1997).

**EXAMINER** \_\_\_\_\_ **DATE CONSIDERED** \_\_\_\_\_

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.